| Issue Date |
Title |
Author(s) |
| 2019 |
Appendicular skeletal muscle mass: A more sensitive biomarker of disease severity than BMI in adults with mitochondrial diseases |
Hou, Yue;Xie, Zhiying;Zhao, Xutong;Yuan, Yun;Dou, Pan;Wang, Zhaoxia |
| 2019 |
Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients |
Xie, Zhiying;Hou, Yue;Yu, Meng;Liu, Yilin;Fan, Yanbin;Zhang, Wei;Wang, Zhaoxia;Xiong, Hui;Yuan, Yun |
| 29-Jan-2020 |
Cognitive Profile of Patients With Mitochondrial Chronic Progressive External Ophthalmoplegia |
Zhang, Guanyu;Hou, Yue;Wang, Zhaoxia;Ye, Zheng |
| 2017 |
Direct Chemical Vapor Deposition Growth and Band-Gap Characterization of MoS2/h-BN van der Waals Heterostructures on Au Foils |
Zhang, Zhepeng;Ji, Xujing;Shi, Jianping;Zhou, Xiebo;Zhang, Shuai;Hou, Yue;Qi, Yue;Fang, Qiyi;Ji, Qingqing;Zhang, Yu;Hong, Min;Yang, Pengfei;Liu, Xinfeng;Zhang, Qing;Liao, Lei;Jin, Chuanhong;Liu, Zhongfan;Zhang, Yanfeng |
| Mar-2022 |
Novel and recurrent nuclear gene variations in a cohort of Chinese progressive external ophthalmoplegia patients with multiple mtDNA deletions |
Hou, Yue;Zhao, Xutong;Xie, Zhiying;Yu, Meng;Lv, He;Zhang, Wei;Yuan, Yun;Wang, Zhaoxia |
| 2019 |
Optical coherence tomography findings in chronic progressive external ophthalmoplegia |
Wu, Yuan;Kang, Lei;Wu, Hai-Long;Hou, Yue;Wang, Zhao-Xia |
| 26-Aug-2020 |
Prediction of iatrogenic preterm birth in patients with scarred uterus: a retrospective cohort study in Northeast China |
Zhang, Liyang;Li, Hongtian;Li, Jiapo;Hou, Yue;Xu, Buxuan;Li, Na;Yang, Tian;Liu, Caixia;Qiao, Chong |
| Jul-2021 |
Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment |
Kong, Jun;Qin, Ya-zhen;Zhao, Xiao-Su;Hou, Yue;Liu, Kai-yan;Huang, Xiao-jun;Jiang, Hao |
| 2018 |
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study |
Jiang, Qian;Huang, Xiao Jun;Chen, Zi;Men, Lichuang;Liu, Wei;Sun, Xuemei;Ji, Jiao;Wang, Hengbang;Hou, Yue;Hu, Po;Zou, Lei;Yan, Hua;Huang, Yingjie;Yang, Dajun;Zhai, Yifan |
| 23-Nov-2021 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Song, Yongping;Zhang, Gongli;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yujun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation |
Jiang, Qian;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Zhang, Yanli;Song, Yongping;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yu-Jun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
